 |
 |
 |
|||
EnWave to Test Animal Vaccines |
|||||
|
EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") has signed an agreement with the Saskatchewan Research Council (SRC) to install the Company’s freezeREV in-vial pharmaceutical dehydration technology for animal vaccine testing at the SRC Fermentation Pilot Plant in Saskatoon, Saskatchewan. SRC scientists will conduct a series of viability and shelf-life tests using two proprietary Escherichia coli (“E.coli”) vaccines for swine to determine the potential benefits of EnWave’s dehydration technology over the current preservation method, freeze drying. Following the testing of SRC’s E.coli vaccines, SRC will make their facilities available to third-party producers of vaccines to conduct their own testing of EnWave’s freezeREV technology on a fee-for-service basis. SRC will also use their extensive industry expertise to evaluate the current freezeREV prototype and provide input into EnWave’s current design concepts for the next generation multi-vial prototype.
This is an important step for EnWave in moving the development of our potentially ground-breaking freezeREV pharmaceutical dehydration technology forward. Because we do not have a laboratory capable of handling pathogenic material such as vaccines, the SRC facility can be used on a fee-for-service basis when EnWave wishes to test a partner's vaccine. Through their trained staff and pilot plant facilities, EnWave essentially has immediate access to a laboratory for testing a wide variety of live or active pharmaceutical materials. |
||||
 |
 |
 |
